| CASE REPORT |
|
| Year : 2012 | Volume
: 44
| Issue : 2 | Page : 270-271 |
Severe hypercalcemia due to teriparatide
Cumali Karatoprak1, Kadir Kayatas2, Hanifi Kilicaslan3, Servet Yolbas1, Nurhan Aliye Yazimci2, Tolga Gümüskemer2, Refik Demirtunç2
1 Internal Medicine Clinic, Bezmialem Vakif University Medical School Hospital, Istanbul, Turkey
2 Internal Medicine Clinic, Haydarpasa Numune Training and Research Hospital, Istanbul, Turkey
3 Internal Medicine, Can Private Hospital, Bitlis, Tatvan, Turkey
Correspondence Address:
Cumali Karatoprak
Internal Medicine Clinic, Bezmialem Vakif University Medical School Hospital, Istanbul
Turkey
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/0253-7613.93869
Osteoporosis that is by far the most common metabolic bone disease, has been defined as a skeletal disorder characterized by compromised bone strength predisposing a person to an increased risk of fracture. Anabolic therapy with teriparatide, recombinant human parathyroid hormone (PTH 1-34), stimulates bone formation and resorption and improves trabecular and cortical microarchitecture. Teriparatide is indicated for the treatment of men and postmenopausal women with osteoporosis who are at high risk for fracture, including those who have failed or are intolerant of previous osteoporosis therapy. In conclusion, although teriparatide seems quite effective in the treatment of osteoporosis, it may cause life-threatening hypercalcemia. Therefore, patients should be closely monitored if symptoms of hypercalcemia are present during teriparatide treatment. Sustained hypercalcemia due to teriparatide treatment can not be seen in literature so we wanted to emphasize that severe hypercalcemia may develop due to teriperatide.
[FULL TEXT] [PDF]*
|
